GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunome Inc (NAS:IMNM) » Definitions » Dividend Payout Ratio

IMNM (Immunome) Dividend Payout Ratio : 0.00 (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Immunome Dividend Payout Ratio?

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Immunome's Dividend Payout Ratio for the months ended in Sep. 2024 was 0.00.

The historical rank and industry rank for Immunome's Dividend Payout Ratio or its related term are showing as below:


IMNM's Dividend Payout Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 0.48
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-12-12), the Dividend Yield % of Immunome is 0.00%.

Immunome's Dividends per Share for the months ended in Sep. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.


Immunome Dividend Payout Ratio Historical Data

The historical data trend for Immunome's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunome Dividend Payout Ratio Chart

Immunome Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Dividend Payout Ratio
Get a 7-Day Free Trial - - - - -

Immunome Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Dividend Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Immunome's Dividend Payout Ratio

For the Biotechnology subindustry, Immunome's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunome's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunome's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Immunome's Dividend Payout Ratio falls into.



Immunome Dividend Payout Ratio Calculation

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.

Immunome's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio=Dividends per Share (A: Dec. 2023 )/ EPS without NRI (A: Dec. 2023 )
=0/ -1.308
=N/A

Immunome's Dividend Payout Ratio for the quarter that ended in Sep. 2024 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Sep. 2024 )/ EPS without NRI (Q: Sep. 2024 )
=0/ -0.669
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immunome (NAS:IMNM) Dividend Payout Ratio Explanation

In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.


Immunome Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Immunome's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunome Business Description

Traded in Other Exchanges
N/A
Address
18702 N. Creek Parkway, Suite 100, Bothell, WA, USA, 98011
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
Executives
Clay B Siegall director, officer: President and CEO 21823 30TH DR SE, BOTHELL WA 98021
Robert Lechleider officer: Chief Medical Officer C/O IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300 PA 19341
Max Rosett officer: SVP Operations C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
Jean Jacques Bienaime director 925 PAGE MILL ROAD, PALO ALTO CA 94304
Jack Higgins officer: Chief Scientific Officer C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
Isaac Barchas director, other: See remarks 1601 BRYAN STREET, SUITE 4141, DALLAS TX 75201
Bruce Turner officer: Chief Strategy Officer C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
James P Boylan director C/O ENAVATE SCIENCES, 2884 SAND HILL RD., STE 100, MENLO PARK CA 94025
Matthew K Robinson officer: Chief Technology Officer C/O IMMUNOME, INC., 665 STOCKTON DRIVE SUITE 300, EXTON PA 19341
Michael Rapp director, 10 percent owner 712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019
Franklyn G Prendergast director
Michael Lefenfeld director IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON PA 19341
Purnanand D Sarma director, officer: President and CEO IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON PA 19341
John L Lamattina director 81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454
Philip Wagenheim director 712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019